-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sickle cell disease (SCD) is a genetic disorder of the hemoglobin molecule.
When the hemoglobin molecule is exposed to various environments, the red blood cell hemoglobin polymerizes and twists into a sickle shape
.
This deformation allows red blood cells to pass between cells, resulting in damage to downstream tissue nutrition
Sickle cell disease (SCD) is a genetic disorder of the hemoglobin molecule.
Monensin plasma carrier can promote the transmembrane transport of red blood cell membrane sodium, increase the permeability of red blood cell membrane sodium, cause the osmotic expansion of red blood cells, and reduce hemoglobin concentration
.
Therefore, in a foreign study, the research team treated the blood samples of 13 SCD patients with 10 nM monensin
In a foreign study, the research team used 10 nM monensin to treat blood samples from 13 patients with SCD
Figure 1 Data collection and analysis: A) Schematic diagram of monensin treatment workflow
.
(B) Representative image of raw speed data
Figure 1 Data collection and analysis: A) Schematic diagram of monensin treatment workflow
Figure 2: Related parameter analysis
.
(A) MCV and MCHC are not correlated (r=-0.
Figure 2: Related parameter analysis
Figure 3: The therapeutic effect and variability of monensin
.
(AB) The effect of monensin on MCHC and MCV
Figure 3: The therapeutic effect and variability of monensin
Figure 4: Linear correlation analysis
.
Pearson correlation coefficient analysis is used to determine the strength of the linear relationship
.
(A) The change of MCV was significantly positively correlated with the change of MCHC (r=0.
91, p<0.
001)
.
(B) Speed recovery and MCV change are also positively correlated (r=0.
87, p<0.
001)
.
(C) The correlation between speed recovery and MCHC change is the strongest (r=0.
96, p<0.
01)
.
Figure 4: Linear correlation analysis
.
Pearson correlation coefficient analysis is used to determine the strength of the linear relationship
.
(A) The change of MCV was significantly positively correlated with the change of MCHC (r=0.
91, p<0.
001)
.
(B) Speed recovery and MCV change are also positively correlated (r=0.
87, p<0.
001)
.
(C) The correlation between speed recovery and MCHC change is the strongest (r=0.
96, p<0.
01)
.
Although the degree of response of different samples is different, in most blood samples, monensin treatment causes an increase in cell volume and a decrease in hemoglobin concentration
.
The monensin-treated samples also showed reduced blood flow damage under hypoxic conditions relative to the untreated control group
.
In addition, there is a significant correlation between the improvement of blood flow and the decrease of hemoglobin concentration
.
Monensin treatment leads to an increase in cell volume and a decrease in hemoglobin concentration.
The improvement of blood flow is significantly correlated with the decrease of hemoglobin concentration.
The improvement of blood flow is related to the decrease of hemoglobin concentration.
Significant correlation
Therefore, the results of this study indicate that reducing intracellular HbS concentration through osmotic swelling can improve blood flow under hypoxic conditions
.
Although the toxicity of monensin makes it impossible to become a viable clinical treatment, the results still suggest that osmotic swelling as a potential mechanism for SCD treatment should be further studied
.
Reduced intracellular HbS concentration by osmotic swelling can improve blood flow under hypoxic conditions.
Although monensin's toxicity makes it impossible to become a viable clinical practice.
Treatment method.
Although monensin's toxicity makes it impossible to be a feasible clinical treatment method, osmotic swelling as a potential mechanism of SCD treatment should be further studied
.
Osmotic swelling as a potential mechanism of SCD treatment should be further studied
.
Original source:
Leave a message here